sesión inmunoterapia - dr. ralph mosges
DESCRIPTION
Conferencia dictada en el XVII Congreso Latinoamericano de Alergia, Asma e Inmunología, Cartagena, 2012TRANSCRIPT
Prof. Dr. Paolo Falagiani (1947 – 2011)
1: Liccardi G, Passalacqua G, Salzillo A, Piccolo A, Falagiani P, Russo M,
Canonica GW, D'Amato G. Is sensitization to furry animals an independent allergic
phenotype in nonoccupationally exposed individuals? J Investig Allergol Clin
Immunol. 2011;21(2):137-41. PubMed PMID: 21462804.
2: Petrarca C, Lazzarin F, Pannellini T, Iezzi M, Braga M, Mistrello G, Falagiani
P, Di Giampaolo L, Di Gioacchino M. Monomeric allergoid intragastric
administration induces local and systemic tolerogenic response involving
IL-10-producing CD4(+)CD25(+) T regulatory cells in mice. Int J Immunopathol
Pharmacol. 2010 Oct-Dec;23(4):1021-31. PubMed PMID: 21244752.
3: Marogna M, Massolo A, Colombo F, Isella P, Bruno M, Falagiani P. Children
passive smoking jeopardises the efficacy of standard anti-allergic
pharmacological therapy, while sublingual immunotherapy withstands. Allergol
Immunopathol (Madr). 2011 Mar-Apr;39(2):60-7. Epub 2011 Jan 7. PubMed PMID:
21216083.
4: Marogna M, Colombo F, Cerra C, Bruno M, Massolo A, Canonica GW, Falagiani P,
Passalacqua G. The clinical efficacy of a sublingual monomeric allergoid at
different maintenance doses: a randomized controlled trial. Int J Immunopathol
Pharmacol. 2010 Jul-Sep;23(3):937-45. PubMed PMID: 20943066.
5: Liccardi G, Dente B, Restani P, Senna G, Falagiani P, Ballabio C, D'Amato G.
Respiratory allergy induced by exclusive polysensitization to serum albumins of
furry animals. Eur Ann Allergy Clin Immunol. 2010 Jun;42(3):127-30. PubMed PMID:
20648777.
6: D'Anneo RW, Bruno ME, Falagiani P. Sublingual allergoid immunotherapy: a new
4-day induction phase in patients allergic to house dust mites. Int J
Immunopathol Pharmacol. 2010 Apr-Jun;23(2):553-60. PubMed PMID: 20646350.
7: Leonardi S, Arena A, Bruno ME, Cannaò PM, D'Anneo RW, Falagiani P, Gammeri E,
Mistrello G, Nicolini A, Ricciardi L, Valenti G, Longo R, La Rosa M. Olea
sublingual allergoid immunotherapy administered with two different treatment
regimens. Allergy Asthma Proc. 2010 Mar-Apr;31(2):e25-9. PubMed PMID: 20406589.
8: Minelli M, Schiavino D, Musca F, Bruno ME, Falagiani P, Mistrello G, Riva G,
Braga M, Turi MC, Di Rienzo V, Petrarca C, Schiavone C, Di Gioacchino M. Oral
hyposensitization to nickel induces clinical improvement and a decrease in TH1
and TH2 cytokines in patients with systemic nickel allergy syndrome. Int J
Immunopathol Pharmacol. 2010 Jan-Mar;23(1):193-201. PubMed PMID: 20378005.
9: Agostinis F, Foglia C, Bruno ME, Falagiani P. Efficacy, safety and
tolerability of sublingual monomeric allergoid in tablets given without up-dosing
to pediatric patients with allergic rhinitis and/or asthma due to grass pollen.
Eur Ann Allergy Clin Immunol. 2009 Dec;41(6):177-80. PubMed PMID: 20128231.
10: Burastero SE, Mistrello G, Paolucci C, Breda D, Roncarolo D, Zanotta S,
Falagiani P. Clinical and immunological correlates of pre-co-seasonal sublingual
immunotherapy with birch monomeric allergoid in patients with allergic
rhinoconjunctivitis. Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):343-52.
PubMed PMID: 19505388.
11: Di Gioacchino M, Perrone A, Petrarca C, Di Claudio F, Mistrello G, Falagiani
P, Dadorante V, Verna N, Braga M, Ballone E, Cavallucci E. Early cytokine
modulation after the rapid induction phase of sublingual immunotherapy with mite
monomeric allergoids. Int J Immunopathol Pharmacol. 2008 Oct-Dec;21(4):969-76.
PubMed PMID: 19144282.
12: Liccardi G, Passalacqua G, Falagiani P, Russo M, D'Amato G. The effect of
multiple allergens on histamine release in vivo assessed by skin prick test.
Allergy. 2008 Nov;63(11):1559-60. PubMed PMID: 18925893.
13: Marogna M, Bruno ME, Massolo A, Falagiani P. Sublingual immunotherapy for
allergic respiratory disease in elderly patients: a retrospective study. Eur Ann
Allergy Clin Immunol. 2008 May;40(1):22-9. PubMed PMID: 18700331.
14: D'Anneo RW, Arena A, Gammeri E, Bruno ME, Falagiani P, Riva G, Leonardi S, La
Rosa M. Parietaria sublingual allergoid immunotherapy with a co-seasonal
treatment schedule. Allergol Immunopathol (Madr). 2008 Mar-Apr;36(2):79-84.
PubMed PMID: 18479659.
15: Burastero SE, Mistrello G, Falagiani P, Paolucci C, Breda D, Roncarolo D,
Zanotta S, Monasterolo G, Rossi RE. Effect of sublingual immunotherapy with grass
monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10
production. Ann Allergy Asthma Immunol. 2008 Apr;100(4):343-50. PubMed PMID:
18450120.
16: Falagiani P. Nickel hyposensitization: a literature review. Int J
Immunopathol Pharmacol. 2005 Oct-Dec;18(4 Suppl):3-5. Review. PubMed PMID:
17761097.
17: Mistrello G, Harfi H, Roncarolo D, Kwaasi A, Zanoni D, Falagiani P, Panzani
R. Date palm pollen allergoid: characterization of its chemical-physical and
immunological properties. Int Arch Allergy Immunol. 2008;145(3):224-30. Epub 2007
Oct 3. PubMed PMID: 17914274.
18: Andri L, Falagiani P. Safety of celecoxib in patients with cutaneous
reactions due to ASA-NSAIDs intolerance. Allergol Immunopathol (Madr). 2007
Jul-Aug;35(4):126-9. PubMed PMID: 17663920.
19: Giordano T, Quarta C, Bruno ME, Falagiani P, Riva G. Safety, tolerability and
efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up
phase. Eur Ann Allergy Clin Immunol. 2006 Nov;38(9):310-2. PubMed PMID: 17191751.
20: Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL, Palma-Carlos ML,
Bruno ME, Falagiani P, Riva G. Clinical efficacy and safety of preseasonal
sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic
patients. A double-blind, placebo-controlled study. Allergol Immunopathol (Madr).
2006 Sep-Oct;34(5):194-8. PubMed PMID: 17064648.
21: Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of
sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial
hyperreactivity: A long-term (13-year) retrospective study in real life. Int Arch
Allergy Immunol. 2007;142(1):70-8. Epub 2006 Oct 2. PubMed PMID: 17016060.
22: Baruffini A, Pisati G, Russello M, Falagiani P. [Occupational allergic
IgE-mediated disease from Boletus edulis: case report]. Med Lav. 2005
Nov-Dec;96(6):507-12. Italian. Erratum in: Med Lav. 2006 Jan-Feb;97(1):87. PubMed
PMID: 16983976.
23: Passalacqua G, Pasquali M, Ariano R, Lombardi C, Giardini A, Baiardini I,
Majani G, Falagiani P, Bruno M, Canonica GW. Randomized double-blind controlled
study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due
to mites. Allergy. 2006 Jul;61(7):849-54. PubMed PMID: 16792583.
24: Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O,
Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Sublingual immunotherapy
with Dermatophagoides monomeric allergoid down-regulates allergen-specific
immunoglobulin E and increases both interferon-gamma- and
interleukin-10-production. Clin Exp Allergy. 2006 Mar;36(3):261-72. PubMed PMID:
16499636.
55: Liccardi G, Russo M, Mistrello G, Falagiani P, D'Amato M, D'Amato G.
Sensitization to pistachio is common in Parietaria allergy. Allergy. 1999
Jun;54(6):643-5. PubMed PMID: 10435484.
25: Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Falagiani P,
Canonica GW, Passalacqua G. Pharmacokinetics of Der p 2 allergen and derived
monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol. 2005
Nov;138(3):197-202. Epub 2005 Oct 3. PubMed PMID: 16205097.
26: Passalacqua G, Altrinetti V, Mariani G, Falagiani P, Mistrello G, Brizzolara
R, Canonica GW, Bagnasco M. Pharmacokinetics of radiolabelled Par j 1
administered intranasally to allergic and healthy subjects. Clin Exp Allergy.
2005 Jul;35(7):880-3. PubMed PMID: 16008673.
27: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Why do lipid
transfer protein-hypersensitive patients tolerate bean (and other legumes)? Int
Arch Allergy Immunol. 2005 Jul;137(3):236-40. Epub 2005 Jun 13. PubMed PMID:
15956792.
28: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Detection of novel
latex allergens associated with clinically relevant allergy to plant-derived
foods. J Allergy Clin Immunol. 2005 Jun;115(6):1312-4. PubMed PMID: 15940153.
29: Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of
sublingual immunotherapy with a monomeric allergoid in very young children.
Allergy. 2005 Jan;60(1):133. PubMed PMID: 15575951.
30: Marogna M, Falagiani P, Bruno M, Massolo A, Riva G. The allergic march in
pollinosis: natural history and therapeutic implications. Int Arch Allergy
Immunol. 2004 Dec;135(4):336-42. Epub 2004 Nov 24. PubMed PMID: 15564776.
31: Lombardi C, Gani F, Landi M, Falagiani P, Bruno M, Canonica GW, Passalacqua
G. Quantitative assessment of the adherence to sublingual immunotherapy. J
Allergy Clin Immunol. 2004 Jun;113(6):1219-20. PubMed PMID: 15214362.
32: Hilger C, Thill L, Grigioni F, Lehners C, Falagiani P, Ferrara A, Romano C,
Stevens W, Hentges F. IgE antibodies of fish allergic patients cross-react with
frog parvalbumin. Allergy. 2004 Jun;59(6):653-60. PubMed PMID: 15147451.
33: Andri L, Falagiani P. Symptomatic relief after grass nasal immunotherapy:
lasting efficacy after 4-5 years. J Investig Allergol Clin Immunol.
2003;13(4):228-31. PubMed PMID: 14989110.
34: Asero R, Mistrello G, Roncarolo D, Amato S, Falagiani P. Analysis of the heat
stability of lipid transfer protein from apple. J Allergy Clin Immunol. 2003
Nov;112(5):1009-11. PubMed PMID: 14610497.
35: Bagnasco M, Morbelli S, Altrinetti V, Falagiani P, Mariani G, Passalacqua G.
Allergen biodistribution in humans. Chem Immunol Allergy. 2003;82:33-43. Review.
PubMed PMID: 12947990.
36: Ballero M, Ariu A, Falagiani P. Allergy to Ailanthus altissima (tree of
heaven) pollen. Allergy. 2003 Jun;58(6):532-3. PubMed PMID: 12757458.
37: Mistrello G, Roncarolo D, Zanoni D, Zanotta S, Amato S, Falagiani P, Ariano
R. Allergenic relevance of Cupressus arizonica pollen extract and biological
characterization of the allergoid. Int Arch Allergy Immunol. 2002
Dec;129(4):296-304. PubMed PMID: 12483034.
38: Di Rienzo V, Falagiani P, Frati F, Sensi L, Marcucci F. Unusual IgE-mediated
allergy to fish bait. Allergy. 2002 Sep;57(9):869-70. PubMed PMID: 12169198.
39: Meglio P, Plantamura M, Arabito E, Falagiani P, Torre A, Rossi P. Does SIT to
Der p protect from snail sensitization? Allergy. 2002 Sep;57(9):868-9. PubMed
PMID: 12169197.
40: Tripodi S, Falagiani P, Perinelli T, Dell'Omo F, Cristaldi A. Allergy to
fishing bait. Allergy. 2002 Jul;57(7):653. PubMed PMID: 12100315.
41: Pocobelli D, Del Bono A, Venuti L, Falagiani P, Venuti A. Nasal immunotherapy
at constant dosage: a double-blind, placebo-controlled study in grass-allergic
rhinoconjunctivitis. J Investig Allergol Clin Immunol. 2001;11(2):79-88. PubMed
PMID: 11642577.
42: Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW,
Passalacqua G. Safety of sublingual immunotherapy with monomeric allergoid in
adults: multicenter post-marketing surveillance study. Allergy. 2001
Oct;56(10):989-92. PubMed PMID: 11576079.
43: Asero R, Mistrello G, Roncarolo D, Casarini M, Falagiani P. Allergy to
nonspecific lipid transfer proteins in Rosaceae: a comparative study of different
in vivo diagnostic methods. Ann Allergy Asthma Immunol. 2001 Jul;87(1):68-71.
PubMed PMID: 11476467.
44: Passalacqua G, Villa G, Altrinetti V, Falagiani P, Canonica GW, Mariani G,
Bagnasco M. Sublingual swallow or spit? Allergy. 2001 Jun;56(6):578. PubMed PMID:
11421908.
45: Arena A, Cislaghi C, Falagiani P. Anaphylactic reaction to the ingestion of
raw onion. A case report. Allergol Immunopathol (Madr). 2000 Sep-Oct;28(5):287-9.
PubMed PMID: 11270091.
46: Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani
P, Mistrello G, Canonica GW, Mariani G. Pharmacokinetics of an allergen and a
monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp
Allergy. 2001 Jan;31(1):54-60. PubMed PMID: 11167951.
47: Angiola Crivellaro M, Senna G, Riva G, Cislaghi C, Falagiani P, Walter
Canonica G, Passalacqua G. Pollen mixtures used as health food may be a harmful
source of allergens. J Investig Allergol Clin Immunol. 2000 Sep-Oct;10(5):310-1.
PubMed PMID: 11108445.
48: Senna GE, Andri G, Dama AR, Falagiani P, Andri L. Local nasal immunotherapy:
efficacy and tolerability of two different administration schedules in grass
pollen rhinitis. Allergol Immunopathol (Madr). 2000 Jul-Aug;28(4):238-42. PubMed
PMID: 11022271.
49: Corsico R, Falagiani P, Ariano R, Berra D, Biale C, Bonifazi F, Campi P,
Feliziani V, Frenguelli G, Galimberti M, Gallesio MT, Liccardi G, Loreti A,
Marcer G, Marcucci F, Meriggi A, Minelli M, Nardelli R, Nardi G, Negrini CA, Papa
G, Piu G, Pozzan M, D'Ambrosio FP, Riva G. An epidemiological survey on the
allergological importance of some emerging pollens in Italy. J Investig Allergol
Clin Immunol. 2000 May-Jun;10(3):155-61. PubMed PMID: 10923590.
50: Romano C, Ferrara A, Falagiani P. A case of allergy to globe artichoke and
other clinical cases of rare food allergy. J Investig Allergol Clin Immunol. 2000
Mar-Apr;10(2):102-4. PubMed PMID: 10879999.
51: Romano C, Ferrara AM, Cislaghi C, Falagiani P. Food allergy to frog. Allergy.
2000 Jun;55(6):584-5. PubMed PMID: 10858996.
52: Falagiani P. Intranasal immunotherapy. Allergy. 1999;54 Suppl 58:53-5.
Review. PubMed PMID: 10735653.
53: Asero R, Mistrello G, Roncarolo D, Casarini M, Falagiani P. True
monosensitivity to a tropical sole. Allergy. 1999 Nov;54(11):1228-9. PubMed PMID:
10604565.
54: Crimi E, Voltolini S, Minale P, Falagiani P. Value of immunoglobulin E
density in predicting nasal and bronchial response to inhaled allergens in
rhinitic and asthmatic subjects with multiple sensitizations. Clin Exp Allergy.
1999 Dec;29(12):1663-70. PubMed PMID: 10594543.
55: Liccardi G, Russo M, Mistrello G, Falagiani P, D'Amato M, D'Amato G.
Sensitization to pistachio is common in Parietaria allergy. Allergy. 1999
Jun;54(6):643-5. PubMed PMID: 10435484.
56: Asero R, Mistrello G, Roncarolo D, Antoniotti PL, Falagiani P. A case of
sesame seed-induced anaphylaxis. Allergy. 1999 May;54(5):526-7. PubMed PMID:
10380788.
57: Asero R, Mistrello G, Roncarolo D, Antoniotti P, Cislaghi C, Falagiani P. A
new apple extract. Allergy. 1999 Jan;54(1):87-8. PubMed PMID: 10195370.
58: Roncarolo D, Minale P, Mistrello G, Voltolini S, Falagiani P. Food allergy to
Boletus edulis. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):850-1. PubMed PMID:
9648715.
59: Passalacqua G, Bagnasco M, Mariani G, Falagiani P, Canonica GW. Local
immunotherapy: pharmacokinetics and efficacy. Allergy. 1998 May;53(5):477-84.
Review. PubMed PMID: 9636806.
60: Mistrello G, Gentili M, Roncarolo D, Antoniotti P, Ottoboni F, Falagiani P.
Dot immunobinding assay for detection of mite antigens in house-dust samples. J
Med Entomol. 1998 Mar;35(2):143-7. PubMed PMID: 9538574.
61: Asero R, Mistrello G, Roncarolo D, Antoniotti PL, Falagiani P. A case of
garlic allergy. J Allergy Clin Immunol. 1998 Mar;101(3):427-8. PubMed PMID:
9525465.
62: Pisati G, Baruffini A, Bernabeo F, Falagiani P. Environmental and clinical
study of latex allergy in a textile factory. J Allergy Clin Immunol. 1998
Mar;101(3):327-9. PubMed PMID: 9525447.
63: Coppola V, Veronesi A, Indraccolo S, Calderazzo F, Mion M, Minuzzo S,
Esposito G, Mauro D, Silvestri B, Gallo P, Falagiani P, Amadori A, Chieco-Bianchi
L. Lymphoproliferative disease in human peripheral blood mononuclear
cell-injected SCID mice. IV. Differential activation of human Th1 and Th2
lymphocytes and influence of the atopic status on lymphoma development. J
Immunol. 1998 Mar 1;160(5):2514-22. PubMed PMID: 9498797.
64: Passalacqua G, Albano M, Pronzato C, Riccio AM, Scordamaglia A, Falagiani P,
Canonica GW. Long-term follow-up of nasal immunotherapy to Parietaria: clinical
and local immunological effects. Clin Exp Allergy. 1997 Aug;27(8):904-8. PubMed
PMID: 9291287.
65: Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P,
Mistrello G, Canonica GW. Absorption and distribution kinetics of the major
Parietaria judaica allergen (Par j 1) administered by noninjectable routes in
healthy human beings. J Allergy Clin Immunol. 1997 Jul;100(1):122-9. PubMed PMID:
9257796.
66: Asero R, Mistrello G, Roncarolo D, Antoniotti P, Falagiani P.
Exercise-induced egg anaphylaxis. Allergy. 1997 Jun;52(6):687-9. PubMed PMID:
9226076.
67: Asero R, Mistrello G, Falagiani P. Oral allergy syndrome from pork. Allergy.
1997 Jun;52(6):684-6. PubMed PMID: 9226073.
68: Zardi O, Zardi EM, Falagiani P, Zardi DM, Zardi MC, Barduagni F, Barduagni O.
[Subcutaneous human dirofilariasis]. Pathologica. 1997 Feb;89(1):31-5. Review.
Italian. PubMed PMID: 9312730.
69: Canonica GW, Passalacqua G, Mariani G, Motta C, Bartolomei M, Mistrello G,
Falagiani P, Bagnasco M. Oral routes for immunotherapy: clinical efficacy and
kinetics of the allergen. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf
A M. 1997;(91):56-64; discussion 64-7. Review. PubMed PMID: 9383892.
70: Falagiani P, Mistrello G. Pharmacokinetics of allergens after local
administration. Allergy. 1997;52(33 Suppl):17-21. Review. PubMed PMID: 9188942.
71: Liccardi G, Mistrello G, Noschese P, Falagiani P, D'Amato M, D'Amato G. Oral
allergy syndrome (OAS) in pollinosis patients after eating pistachio nuts: two
cases with two different patterns of onset. Allergy. 1996 Dec;51(12):919-22.
PubMed PMID: 9020420.
72: D'Amato G, Russo M, Liccardi G, Saggese M, Gentili M, Mistrello G, D'Amato M,
Falagiani P. Comparison between outdoor and indoor airborne allergenic activity.
Ann Allergy Asthma Immunol. 1996 Aug;77(2):147-52. PubMed PMID: 8760781.
73: Mistrello G, Brenna O, Roncarolo D, Zanoni D, Gentili M, Falagiani P.
Monomeric chemically modified allergens: immunologic and physicochemical
characterization. Allergy. 1996 Jan;51(1):8-15. PubMed PMID: 8721522.
74: Andri L, Senna G, Betteli C, Givanni S, Andri G, Dimitri G, Falagiani P,
Mezzelani P. Local nasal immunotherapy with extract in powder form is effective
and safe in grass pollen rhinitis: a double-blind study. J Allergy Clin Immunol.
1996 Jan;97(1 Pt 1):34-41. PubMed PMID: 8568135.
75: Andri L, Senna G, Andri G, Dama A, Givanni S, Betteli C, Dimitri G, Falagiani
P, Mezzelani P. Local nasal immunotherapy for birch allergic rhinitis with
extract in powder form. Clin Exp Allergy. 1995 Nov;25(11):1092-9. PubMed PMID:
8581842.
76: Mistrello G, Gentili M, Falagiani P, Roncarolo D, Riva G, Tinelli M. Dot
immunobinding assay as a new diagnostic test for human hydatid disease. Immunol
Lett. 1995 Jul-Aug;47(1-2):79-85. PubMed PMID: 8537105.
77: Romano C, Sulotto F, Piolatto G, Ciacco C, Capellaro E, Falagiani P,
Constable DW, Verga A, Scansetti G. Factors related to the development of
sensitization to green coffee and castor bean allergens among coffee workers.
Clin Exp Allergy. 1995 Jul;25(7):643-50. PubMed PMID: 8521183.
78: Panzani RC, Falagiani P, Riva G, Delord Y, Mercier P. Screening for atopy in
a coffee-processing factory. Int Arch Allergy Immunol. 1995
May-Jun;107(1-3):443-4. PubMed PMID: 7613207.
79: Ariano R, Panzani RC, Chiapella M, Augeri G, Falagiani P. Local intranasal
immunotherapy with allergen in powder in atopic patients sensitive to Parietaria
officinalis pollen. J Investig Allergol Clin Immunol. 1995 May-Jun;5(3):126-32.
PubMed PMID: 7582157.
80: Panzani RC, Falagiani P, Riva G, Delord Y, Mercier P. Screening for atopy in
a coffee processing factory. Allergol Immunopathol (Madr). 1995
Jan-Feb;23(1):29-34. PubMed PMID: 7631592.
81: Falagiani P, Mistrello G, Rapisarda G, Festa A, Cislaghi C, Zanoni D.
Evaluation of allergenic potency by REAST inhibition. A new tool for the
standardization of allergenic extracts. J Immunol Methods. 1994 Aug
1;173(2):181-90. PubMed PMID: 8046253.
82: D'Amato G, Gentili M, Russo M, Mistrello G, Saggese M, Liccardi G, Falagiani
P. Detection of Parietaria judaica airborne allergenic activity: comparison
between immunochemical and morphological methods including clinical evaluation.
Clin Exp Allergy. 1994 Jun;24(6):566-74. PubMed PMID: 7922776.
83: Mistrello G, Roncarolo D, Gentili M, Zanoni D, Falagiani P. Modified par j I
allergen from P judaica pollen and its rate of absorption in rats. Immunol Lett.
1994 Apr;40(1):31-6. Erratum in: Immunol Lett 1994 Jul;41(2-3):291. PubMed PMID:
7927511.
84: Costa MA, Colombo P, Izzo V, Kennedy H, Venturella S, Cocchiara R, Mistrello
G, Falagiani P, Geraci D. cDNA cloning, expression and primary structure of Par
jI, a major allergen of Parietaria judaica pollen. FEBS Lett. 1994 Mar
21;341(2-3):182-6. PubMed PMID: 8137937.
85: Panzani RC, Mercier P, Delord Y, Riva G, Falagiani P, Reviron D, Auquier P.
Prevalence of patent and latent atopy among a general normal adult population in
the south east of France by RAST investigation and correlation with circulating
total IgE levels. Allergol Immunopathol (Madr). 1993 Nov-Dec;21(6):211-9. PubMed
PMID: 8160568.
86: Caneva E, Di Gennaro P, Farina F, Orlandi M, Rindone B, Falagiani P.
Synthesis and characterization of a penicillin-poly(L-lysine) which recognizes
human IgE anti-penicillin antibodies. Bioconjug Chem. 1993 Sep-Oct;4(5):309-13.
PubMed PMID: 8274512.
87: Andri L, Senna G, Betteli C, Givanni S, Andri G, Falagiani P. Local nasal
immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder
extract. J Allergy Clin Immunol. 1993 May;91(5):987-96. PubMed PMID: 8491949.
88: Ariano R, Panzani RC, Falagiani P, Chiapella M, Augeri G. Respiratory allergy
to the pollen of Mercurialis annua (Euphorbiaceae). Ann Allergy. 1993
Mar;70(3):249-54. PubMed PMID: 8452320.
89: Burastero SE, Lo Pinto G, Goletti D, Cutolo M, Burlando L, Falagiani P.
Rheumatoid arthritis with monoclonal IgE rheumatoid factor. J Rheumatol. 1993
Mar;20(3):489-94. PubMed PMID: 8386767.
90: Panzani RC, Falagiani P, Riva G, Mercier P, Delord. Screening for IgE
mediated allergy among people working in the Marseilles harbour. Allergol
Immunopathol (Madr). 1993 Jan-Feb;21(1):25-9. PubMed PMID: 8328353.
91: Andri L, Senna GE, Betteli C, Givanni S, Andri G, Falagiani P, Lugo G. Local
nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled
study. Allergy. 1992 Aug;47(4 Pt 1):318-23. PubMed PMID: 1443452.
92: Bolzacchini E, Di Gennaro P, Di Gregorio G, Rindone B, Falagiani P, Mistrello
G, Sondergaard I. Purification of Phleum pratense pollen extract by
immunoaffinity chromatography and high-performance ion-exchange chromatography. J
Chromatogr. 1991 Jul 12;548(1-2):229-34. PubMed PMID: 1939423.
93: Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P,
Ricci M, Romagnani S. Purified protein derivative of Mycobacterium tuberculosis
and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T
cells with stable and opposite (type 1 T helper or type 2 T helper) profile of
cytokine production. J Clin Invest. 1991 Jul;88(1):346-50. PubMed PMID: 1829097;
PubMed Central PMCID: PMC296040.
94: Bolzacchini E, Di Gennaro P, Di Gregorio G, Rindone B, Falagiani P, Mistrello
G, Sondergaard I. Allergenic fragments in Parietaria judaica pollen extract. J
Chromatogr. 1991 Apr 12;542(2):337-44. PubMed PMID: 1715346.
95: Moscato G, Dellabianca A, Falagiani P, Mistrello G, Rossi G, Rampulla C.
Inhaled furosemide prevents both the bronchoconstriction and the increase in
neutrophil chemotactic activity induced by ultrasonic "fog" of distilled water in
asthmatics. Am Rev Respir Dis. 1991 Mar;143(3):561-6. PubMed PMID: 2001067.
96: Mistrello G, Rapisarda G, Falagiani P. Detection of IgE-binding activity in
serum after intranasal treatment of normal rabbits with P. judaica extract.
Allergy. 1991 Jan;46(1):52-8. PubMed PMID: 2018209.
97: Falagiani P. Thimerosal in standard antigenic extracts. Contact Dermatitis.
1989 Nov;21(5):354. PubMed PMID: 2620521.
98: Cocchiara R, Locorotondo G, Parlato A, Guarnotta G, Ronchi S, Albeggiani G,
Amoroso S, Falagiani P, Geraci D. Purification of Parj I, a major allergen from
Parietaria, judaica pollen. Int Arch Allergy Appl Immunol. 1989;90(1):84-90.
PubMed PMID: 2478488.
99: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, Falagiani P,
Riva G, Bolzacchini E. Micropreparative-scale enrichment of some allergenic
components of Parietaria pollen extract. J Chromatogr. 1988 Jul 27;446:179-85.
PubMed PMID: 3209654.
100: Genchi C, Falagiani P, Riva G, Tinelli M, Brunello F, Boero M, Almaviva M.
IgE and IgG antibodies in Toxocara canis infection. A clinical evaluation. Ann
Allergy. 1988 Jul;61(1):43-6. PubMed PMID: 3389570.
101: Bassoli A, Chioccara F, Di Gregorio G, Rindone B, Tollari S, Falagiani P,
Riva G, Bolzacchini E. Analysis of allergenic components of a Parietaria judaica
pollen extract by chromatographic methods for the evaluation of purification
procedures. J Chromatogr. 1988 Jul 1;444:209-18. PubMed PMID: 3204131.
102: Bolzacchini E, Di Gregorio G, Nali M, Rindone B, Tollari S, Falagiani P,
Riva G, Crespi G. Purification and molecular weight studies on the components of
a Parietaria pollen extract. Allergy. 1988 Jan;43(1):53-9. PubMed PMID: 3344935.
103: Amoroso S, Cocchiara R, Locorotondo G, Parlato A, Lampiasi N, Albeggiani G,
Falagiani P, Geraci D. Antigens of Euparipha pisana (snail). I. Identification of
allergens by means of in vivo and in vitro analysis. Int Arch Allergy Appl
Immunol. 1988;85(1):69-75. PubMed PMID: 2448245.
104: Tinelli M, Falagiani P, Riva G, Genchi C. RAST and ELISA in three
autochthonous parasitic infections in Italy: toxocariasis, hydatidosis and
fascioliasis. Boll Ist Sieroter Milan. 1987;66(1):38-45. PubMed PMID: 3620121.
105: Sgambato F, Pedicini A, De Rienzo D, Falagiani P. [Inhalation allergy to fly
larva. A clinical case]. Boll Ist Sieroter Milan. 1987;66(5):411-5. Italian.
PubMed PMID: 3449104.
106: Boner AL, Vallone G, Bennati D, Falagiani P, Gaburro D. Simplified spinhaler
method for antigen-specific bronchoprovocation in children with bronchial asthma.
I. Ann Allergy. 1986 Nov;57(5):363-6. PubMed PMID: 3777536.
107: Brunello F, Falagiani P, Genchi C. Enzyme immunoassay (ELISA) for the
detection of specific IgG antibodies to Toxocara canis ES antigens. Boll Ist
Sieroter Milan. 1986;65(1):54-60. Erratum in: Boll Ist Sieroter Milan
1986;65(5):following 445. PubMed PMID: 3718679.
08: Genchi C, Tinelli M, Brunello F, Falagiani P. Serodiagnosis of ocular
toxocariasis: a comparison of specific IgE and IgG. Trans R Soc Trop Med Hyg.
1986;80(6):993-4. PubMed PMID: 3603652.
109: Falagiani P, Cavallone E, Nali M, Rindone B, Tollari S, Crespi G. Aqueous
size-exclusion analysis of Parietaria pollen extracts. J Chromatogr. 1985 Jun
28;328:425-31. PubMed PMID: 4030974.
An impressively productive scientific mind
Il dosaggio radio-immunologico delle reagine del secreto nasale.
• Boll Soc Ital Biol Sper.
• 1977 Feb 15 ; 53(3):188-92.
• Crifò S, Falagiani P, Filiaci F, Andriani G.
The author of numerous books
Concept of the monomeric allergoid
The novel view on specific
immunotherapy
The Idea:
To combine the advantages of allergoids together with the
sublingual route into a better effective and more safe
Immunotherapy
The first specific sublingual immuntherapy with allergoids available as tablets & drops
Maintained conformation for T-cell-binding
Chemical modification of residual peripheral
aminoacid-sequences Reduced IgE binding affinity
Allergens The unmodified molecule is destroyed
by the attack of enzymes.
Sublingual Allergoides the modified molecule resists to
enzymatic coupling and remains intact.
The first specific sublingual immuntherapy with allergoids available as tablets & drops
The novel approach
Allergen extracts are chemically transformed, the Carbamylation, to replace parts of the protein components, and to maintain the molecular dimensions.
Monomerization (Monoid)
The first specific sublingual immuntherapy with allergoids available as tablets & drops
1-Reduction of the Allergenicity
2-Maintenance of the Antigenicity
3-Maintenance of the Molecular Dimension
4-Resistance against Enzymatic Digestion
5-Absence of Toxicity
Characterization of the sublingual carbamylated allergoid (Monoid)
Concept Overview
Allergen Type Antigenity Allergenicit
y
Proteine
Structure
Enzymatic
Protection
Monoid Maintained Reduced
(targeted)
Modified,
complex
(„Segments
cut“)
Shown
Native Allergen Maintained Maintained Nativ, complex Not shown
Allergoid
Reduced
(Not
targeted)
Reduced
(targeted) Polymerized Not shown
Allergoid
SLIT
oral
mucosa
gastrointestinal
mucosa
APC Lymphozytes
Lymphatic
system
systemic
circulation
capillaries
clinical
results
Route of action in the oromucosal and gastrointestinal system
Pharmacokinetics
& Immunology
To study the pharmacokinetics
in allergic volunteers
of allergoid sublingual immunotherapy
in oromucosal tablets
Objective
Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E,
Falagiani P, Mistrello G, Canonica GW, Mariani G.. Clinical Immunology Service, DIMI, Genoa, Italy
Radiolabelled monomeric allergoid and native allergen, administered to 8
allergic pts and 1 non atopic, were detected by scintigraphic acquisitions.
Plasma radioactivity was measured at different intervals.
Methods
The increased resistance to gastrointestinal enzymatic degradation can explain
the high absorption of the monomeric allergoid and its appearance in the
bloodstream.
The local persistence of the monomeric allergoid and allergen may involve the
mucosal immunity in the mechanism of action of antiallergic vaccination.
Results
Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E,
Falagiani P, Mistrello G, Canonica GW, Mariani G.. Clinical Immunology Service, DIMI, Genoa, Italy
Pla
sm
ati
c R
ad
ioacti
vit
y
Hrs after application
Sublingual allergoids
in form of tablets
Native Allergens
in form of tablets
Native Allergens
in liquid solution
I
2
I
5
I
1
I
15
1 -
3 -
5 -
ALLERGO Kinetics
Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
M. Bagnasco et al. Clinical Immunology Service, DIMI, Genoa, Italy
Systemic absorption
Mucosal immunity involvement
Conclusions
Clin Exp Allergy 2001, 31; 54-60
Pharmacokinetics of an allergen and a monomeric
allergoid for oromucosal immunotherapy
in allergic volunteers
M. Bagnasco et al. Clinical Immunology Service, DIMI, Genoa, Italy
Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O,
Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Objective
Methods
To show the immunological effects of a sublingual carbamylated allergoid.
25 pts: with rhinitis / asthma to Der p1, positive to
anamnesis, prick, RAST, SNPT and MCH.
Protocol: double blind vs placebo. 1,5 years of treatment.
Treated group: 12 Lais Der p1
Placebo group: 13
the sublingual allergoid increases the
production of the cytokines IL-10 & IFN-
Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
L. Cosmi et al. Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Results
the sublingual allergoid reduces the
production of spezific IgE
Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
L. Cosmi et al. Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Results
Clear immunological effects have been shown under
treatment with a sublingual carbamylated allergoid.
Clin Exp Allergy 2006, 36; 261-272
Sublingual immunotherapy in Dermatophagoides monomeric
allergoid down-regulates allergen-specific immunoglobulin E
and increases both interferon- and interleukin-10-production.
L. Cosmi et al. Center of Research, Transfer, High Education “DENOthe”, University Firenze, Italy
Conclusion
DBPC Trials Results
Sublingual Allergoids
efficacy (subjective data)
• Reduction of symptoms of asthma • Reduction of symptoms of rhinoconjunctivitis • Reduction of symptomatic medication
Results from recent (DBPC) Trials
Sublingual allergoids
efficacy (objective data) Efficacy was assessed using objective measurements:
• increase of the provocative dose specifically in nasal provocation test
unspecifically with Metacholine
Results from recent (DBPC) Trials
Sublingual allergoids
Safety
The safety of treatment is supported by numerous published clinical studies. The sublingual allergoid, the Monoid, has demonstrated its safety also in patients with Oral Allergy Syndrome (OAS).
Results from recent (DBPC) Trials
Sublingual allergoids
Tolerability Tolerability is supported by data from numerous clinical trials
Results from recent (DBPC) Trials
Sublingual allergoids
Compliance Compliance, adherence with the treatment is excellent as demonstrated by:
•Pill count in clinical trials. •Repetitive prescription in real life studies.
Results from recent (DBPC) Trials
Results from recent (DBPC) Trials
Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni Paediatric Departments of Parma, Perugia and Sassuolo, Italy
Material & methods
48 pts: 8 yrs mean age, Rhinoconjunctivitis/Asthma
to Grass. DBPC study. Positive anamnesis,
SPT and RAST. ECP, symptoms, drug score
and Compliance recorded.
Protocol: preseasonal scheduling.
IT treated: 24 Lais Grass.
Drug treated: 20 (4 drop out).
Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni Paediatric Departments of Parma, Perugia and Sassuolo, Italy
Statistically significant differences in
Allergoid SLIT treated group:
Reduced symptom & medication scores in pollen season
Good compliance.
Results
No differences in placebo group.
Reduction of total symptom score during treatment with sublingual allergoids vs Placebo
During the grass pollen season.
sco
re
5 -
I Symptome
NASAL
N S
10 -
15 -
I Symptome
OCULAR
N S p<0.05
I Symptome
BRONCHIAL
I Symptome
TOTAL
p<0.05
I Rescue medication
N S
Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni Paediatric Departments of Parma, Perugia and Sassuolo, Italy
Allergy, 2000: 55: 1-6
Preseasonal local allergoid immunotherapy to grass pollen
in children: a double-blind, placebo-controlled, randomized
trial
C.Caffarelli, L.G.Sensi, F.Marcucci, G.Cavagni Paediatric Departments of Parma, Perugia and Sassuolo, Italy
The preseasonal course with Lais Grass
as Allergoid SLIT:
is effective in the reduction of respiratory
symptoms of children,
in particular asthma, within 3,5 months
Conclusions
Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,
Palma-Carlos ML, Bruno ME, Falagiani P, Riva G. Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
33 pts: with rhinitis / asthma to Phl p5, positive to
anamnesis, prick, RAST, SNPT and MCH.
Protocol: double blind vs placebo
Treated group: 17 Lais 3-Gras Mix
Placebo group: 16
Material & Methods
Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,
Palma-Carlos ML, Bruno ME, Falagiani P, Riva G. Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Design
Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
Palma-Carlos AG, Santos AS, Branco-Ferreira M, Pregal AL,
Palma-Carlos ML, Bruno ME, Falagiani P, Riva G. Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Results
Improvement of the nasal provocation test
Reduction of rhinoconjunctivitis symptoms
Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
Results Reduction of steroid consumption
Allergol et Immunopathol 2006; 34 (5): 194 – 198.
Clinical efficacy and safety of preseasonal sublingual
immunotherapy with gras pollen carbamylated allergoid in
rhinitic patients. A double-blind, placebo-controlled study.
A.G. Palma-Carlos, A.S. Santos, M. Branco-Ferreira, A.L. Pregal Clinical Allergy Immunology Center. CAIC. Lisbon, Portugal
SLIT in gras allergic patients is effective and reduces
single symptoms between 40 - 60 %
and
co-medication (steroids) vs. placebo up to 80%
(at pollen peak)
Conclusions
Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)
Efficacy and safety of oral immunotherapy in respiratory
allergy to Parietaria judaica pollen.
A double blind study
R.Ariano*, R.C.Panzani** and C.Augeri* *Allergy Dept., Bordighera, Italy
**Lab. De Recherches, Marseille, France
30 pts: with rhinitis / asthma to Par j, positive to
anamnesis, prick, RAST, SNPT and MCH.
Protocol: double blind vs placebo. Dec.92 to Jul.95.
Treated group: 15 Lais Par j (1 drop out).
Placebo group: 15
Material & methods
Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)
Efficacy and safety of oral immunotherapy in respiratory
allergy to Parietaria judaica pollen.
A double blind study
R.Ariano*, R.C.Panzani** and C.Augeri* *Allergy Dept., Bordighera, Italy
**Lab. De Recherches, Marseille, France
Statistically significant differences in the
Allergoid SLIT treated group:
Reduced symptoms score (in particular during pollen season).
Reduced medication score.
Increased threshold dose with Allerkin Test.
Increased threshold dose with Methacholine Lofarma.
Results
No differences in placebo group.
Invest Allergol Clin Immunol, May-June 1998 Vol 8 (3)
Efficacy and safety of oral immunotherapy in respiratory
allergy to Parietaria judaica pollen.
A double blind study
R.Ariano*, R.C.Panzani** and C.Augeri* *Allergy Dept., Bordighera, Italy
**Lab. De Recherches, Marseille, France
Hyposensitization with Parietaria pollen as
Allergoid SLIT
is a safe and efficaceous vaccine
which may be used in children and adults.
Conclusions
The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al. Clinical Immunology Service, DIMI, Genoa, Italy
20 pts: per. rhinoconjunctivitis to Der, positive to
anamnesis, prick, RAST and SCPT.
Inflammatory-cells and ICAM-1 and
serum inflam. markers (ECP) recorded.
Protocol: double blind vs placebo. Apr.94 to Mar.96.
Treated group: 10 Lais Der p&f.
Placebo group: 10 (1 drop out).
Material & methods
Statistically significant differences in
The monomeric Allergoid SLIT group:
Reduced symptom & medication scores.
Reduced inflammatory infiltration and ICAM-1 expression.
Reduced MPI, the Minimal Persistent Inflammation.
Results
No differences in placebo group.
The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al. Clinical Immunology Service, DIMI, Genoa, Italy
Reduction of inflammation After 24 months of treatment with sublingual allergoids vs Placebo
Demonstrated by conjunctival provocation test
ICA
M 1
I
24 Months
I
T 0
1 -
3 -
N S
p<0.001 E
OS
INO
FIL
E
I
24 Months
I
T 0
1 -
3 -
N S
0.001
NE
UT
RO
FIL
E
I
24 Months
I
T 0
5 -
10 -
N S
0.001
The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al. Clinical Immunology Service, DIMI, Genoa, Italy
Hyposensitization with Dermatophagoides
as Allergoid SLIT:
l reduces the allergic inflammation
l is safe and clinically effective.
Conclusions
The Lancet Vol.351 Feb 28, 1998
Randomised controlled trial of local allergoid
immunotherapy on allergic inflammation in
house dust mite - induced rhinoconjunctivitis
G. Passalacqua et al. Clinical Immunology Service, DIMI, Genoa, Italy
Giornale Italiano di All e Imm Clin, 2000: 10: S-1
Allergen Specific Oromucosal Immunotherapy: Efficacy and
Safety of a Clustered Scheme of
Treatment for Parietaria Respiratory Allergy
S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri Napoli, Medical Dept Lofarma S.p.A.Italy
Material & methods
39 pts: Rhinoconjunctivitis / Asthma (50%) to Par.
Positive anamnesis, SPT, PFT and SNPT.
Serum inflam. markers (ECP) recorded.
Symptoms & Drug Score, QoL.
Protocol: clustered treatment according to Data Sheet.
IT treated: 27 Lais Par.
Drug treated: 12 (3 drop out).
Giornale Italiano di All e Imm Clin, 2000: 10: S-1
Allergen Specific Oromucosal Immunotherapy: Efficacy and
Safety of a Clustered Scheme of
Treatment for Parietaria Respiratory Allergy
S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri Napoli, Medical Dept Lofarma S.p.A.Italy
Statistically significant differences in
Allergoid SLIT treated group:
Reduced symptom & medication scores.
Improved Quality of Life, assessed by questionnaire.
Good compliance, over 80% .
Results
No differences in placebo group.
Giornale Italiano di All e Imm Clin, 2000: 10: S-1
Allergen Specific Oromucosal Immunotherapy: Efficacy and
Safety of a Clustered Scheme of
Treatment for Parietaria Respiratory Allergy
S.D’Agostino, A.D’Agostino, G.Riva. A.Tiri Napoli, Medical Dept Lofarma S.p.A.Italy
The Clustered Treatment with Parietaria as
Allergoid SLIT:
l is a suitable treatment when it is too
late to start a conventional scheduling
l is well tolerated and safe.
Conclusions
To study the safety of ultra
rush SLIT with four commercial
products in allergic patients.
Objective
Giorn it Allergol Immunol Clin 2002; 12:221-226
Safety of Ultra Rush (two hours) Sublingual
Swallow Immunotherapy in Allergic Patients
R.E. Rossi, G.Monasterolo*
Allergy Unit, National Health Service, Savigliano, Italy
*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy
Ninety-one allergic patients with rhino-conjunctivitis
and/or asthma.
Prospective observational, 36 months follow-up study.
Maintenance phase from Dec 2001 to Mar 2002.
Subdivided in three groups, one was administered the
sublingual allergoid, the others, injective I.T. and drugs.
Material & Methods
Giorn it Allergol Immunol Clin 2002; 12:221-226
Safety of Ultra Rush (two hours) Sublingual
Swallow Immunotherapy in Allergic Patients
R.E. Rossi, G.Monasterolo*
Allergy Unit, National Health Service, Savigliano, Italy
*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy
One adverse event, after 300 IR/ml,
disappeared when adjusted at 30 IR.
No adverse events were noted after
administration of the allergoid SLIT.
Results
Giorn it Allergol Immunol Clin 2002; 12:221-226
Safety of Ultra Rush (two hours) Sublingual
Swallow Immunotherapy in Allergic Patients
R.E. Rossi, G.Monasterolo*
Allergy Unit, National Health Service, Savigliano, Italy
*Laboratorio Analisi Osp. SS.Trinità, Fossano, Italy
To evaluate the efficacy, tolerability
and adherence to treatment of
allergoid sublingual immunotherapy
(I.T.), in comparison with injective
I.T. and drugs.
Objective
Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years prospective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al. *ASL 5, Messina, °Pneumologia, Catania, Italy
One hundred and ten allergic patients with rhino-
conjunctivitis and/or asthma.
Subdivided in three groups, one was administered the
sublingual allergoid, the others injective I.T. and drugs.
Prospective, observational, 36 months follow-up study.
Allergens: pollens and House Dust Mite.
Material & Methods
Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years perspective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al. *ASL 5, Messina, °Pneumologia, Catania, Italy
Sublingual allergoid I.T. was
considered by patients and doctors to
be better than the other two therapies
(p<0.0001) as far as efficacy,
tolerability and patient’s compliance
concern.
Results
Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years perspective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al. *ASL 5, Messina, °Pneumologia, Catania, Italy
Allergoid Sublingual I.T. was
positively appreciated by both
patients and physicians for its
simplicity of use, good efficacy and
the high degree of safety offered.
Conclusions
Int Journ of Immunopathology and Pharmacology, 16, 3;, 277-282
Specific Immunotherapy of allergic disease:
A three years perspective observational study
A. Arena*, E. Barbatano°, E. Gammeri* et al. *ASL 5, Messina, °Pneumologia, Catania, Italy
SLIT with monomeric allergoid
• Effective in rhinoconjunctivitis and asthma
• Impeccable safety also in risk populations
• Perfectly tolerable in adults and children
• Outstanding compliance and adherence
• Internationally accepted by
– The Paul Ehrlich Institute
Thank you for the attention
Paolo Falagiani
1947 - 2011